ADCT-901 is under clinical development by ADC Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADCT-901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADCT-901 is under development for the treatment of solid tumors including platinum-resistant ovarian cancer, bile duct cancer (cholangiocarcinoma), fallopian tube cancer, prostate cancer, renal cell carcinoma and triple-negative breast cancer (TNBC). The drug candidate is a monoclonal antibody drug conjugate which targets cells expressing kidney associated antigen 1 (KAAG1). It is administered through intravenous route.
ADC Therapeutics overview
ADC Therapeutics, is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat solid tumors and hematological cancers. It is investigating Loncastuximab Tesirine (Lonca), an ADC composed of a humanized monoclonal antibody against B-cell hematological tumors; and Camidanlumab Tesirine (Cami) for the treatment of solid tumors. It is also developing ADCT-602 drug for B-cell acute lymphoblastic leukemia; ADCT-601 targeting AXL in solid tumors; ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors; and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and acute myeloid leukemia. The company is a spin-off from Spirogen Ltd. ADC Therapeutics is headquartered in Lausanne, Switzerland.
For a complete picture of ADCT-901’s drug-specific PTSR and LoA scores, buy the report here.